Clene's CNM-Au8 Shows Significant Reduction In Neurodegenerative Biomarker, Raises $40M Via Equity

Clene Inc CLNN reported new data demonstrating a statistically significant reduction of plasma neurofilament light chain (NfL) levels for CNM-Au8 treated participants compared to placebo after 24 weeks in the HEALEY ALS Platform Trial.

NfL is a key biomarker of neurodegeneration. 

Also Read: Clene's Amyotrophic Lateral Sclerosis Candidate Delays Disease Progression, New Data Shows.

CNM-Au8 treatment demonstrated significantly reduced plasma neurofilament light chain levels compared to the placebo at 24 weeks (p=0.04).

In addition to the full analysis across all Regimen C participants, sensitivity analyses showed a consistent significant reduction in plasma NfL levels versus placebo observed in specific populations generally considered at greater risk of ALS disease progression.

Analyses of NfL from serum samples specified as the primary blood matrix for analysis are underway. 

Additional biomarker and long-term survival data from the HEALEY ALS Platform Trial double-blind and open-label extension periods have been collected and are undergoing testing preparatory for analysis to be reported later this year.

Concurrently, Clene priced its underwritten public offering of 50 million shares and two tranches of warrants at a combined price of $0.80 for gross proceeds of $40 million.

Price Action: CLNN shares are down 14.8% at $0.90 on the last check Friday.